Reference
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30.
2. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001 Sep 8;358(9284):781-6.
3. Endo D, Todo Y, Okamoto K, Minobe S, Kato H, Nishiyama N. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort. J Gynecol Oncol. 2015 Jan;26(1):12-8.
4. Chemoradiotherapy for Cervical Cancer Meta-Analysis C. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008 Dec 10;26(35):5802-12.
5. Li X, Wei LC, Zhang Y, Zhao LN, Li WW, Ping LJ, et al. The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy. Int J Gynecol Cancer. 2016 Oct;26(8):1472-9.
6. Chen CC, Wang L, Lin JC, Jan JS. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy. J Formos Med Assoc. 2015 Mar;114(3):231-7.
7. Teh J, Yap SP, Tham I, Sethi VK, Chua EJ, Yeo R, et al. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors. Int J Gynecol Cancer. 2010 Apr;20(3):428-33.
8. Herrera FG, Prior JO. The role of PET/CT in cervical cancer. Front Oncol. 2013;3:34.
9. Guo F, Yang R, Tian J, Fan L. The role of F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) in the screening of cervical cancer: a literature review. Cell Biochem Biophys. 2014 Jun;69(2):197-201.
10. N G, MA A, WE P, AG R, TD B. - FDG-PET Imaging in Cervical Cancer. D - 1264464. (- 1558-4623 (Electronic)):- 461-70.
11. Im HJ, Yoon HJ, Lee ES, Kim TS, Kim JY, Chung JK, et al. Prognostic implication of retrocrural lymph node involvement revealed by (18)F-FDG PET/CT in patients with uterine cervical cancer. Nucl Med Commun. 2014 Mar;35(3):268-75.
12. Chong GO, Jeong SY, Park SH, Lee YH, Lee SW, Hong DG, et al. Comparison of the Prognostic Value of F-18 Pet Metabolic Parameters of Primary Tumors and Regional Lymph Nodes in Patients with Locally Advanced Cervical Cancer Who Are Treated with Concurrent Chemoradiotherapy. PLoS One. 2015;10(9):e0137743.
13. Akkus Yildirim B, Onal C, Erbay G, Cem Guler O, Karadeli E, Reyhan M, et al. Prognostic values of ADCmean and SUVmax of the primary tumour in cervical cancer patients treated with definitive chemoradiotherapy. J Obstet Gynaecol. 2019 Feb;39(2):224-30.
14. Cima S, Perrone AM, Castellucci P, Macchia G, Buwenge M, Cammelli S, et al. Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer. Int J Gynecol Cancer. 2018 Mar;28(3):575-80.
15. Guler OC, Torun N, Yildirim BA, Onal C. Pretreatment metabolic tumour volume and total lesion glycolysis are not independent prognosticators for locally advanced cervical cancer patients treated with chemoradiotherapy. Br J Radiol. 2018 Apr;91(1084):20170552.
16. Lucia F, Visvikis D, Desseroit MC, Miranda O, Malhaire JP, Robin P, et al. Prediction of outcome using pretreatment (18)F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2018 May;45(5):768-86.
17. Hong JH, Jung US, Min KJ, Lee JK, Kim S, Eo JS. Prognostic value of total lesion glycolysis measured by 18F-FDG PET/CT in patients with locally advanced cervical cancer. Nucl Med Commun. 2016 Aug;37(8):843-8.
18. Onal C, Reyhan M, Parlak C, Guler OC, Oymak E. Prognostic value of pretreatment 18F-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy. Int J Gynecol Cancer. 2013 Jul;23(6):1104-10.
19. Lee WK, Chong GO, Jeong SY, Lee HJ, Park SH, Ryu JM, et al. Prognosis-Predicting Model Based on [(18)F]fluorodeoxyglucose PET Metabolic Parameters in Locally Advanced Cervical Cancer Patients Treated with Concurrent Chemoradiotherapy: Multi-Center Retrospective Study. J Clin Med. 2020 Feb 5;9(2).
20. Herrera FG, Breuneval T, Prior JO, Bourhis J, Ozsahin M. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy. Radiat Oncol. 2016 Mar 16;11:43.
21. Yilmaz B, Dag S, Ergul N, Cermik TF. The efficacy of pretreatment and after treatment 18F-FDG PET/CT metabolic parameters in patients with locally advanced squamous cell cervical cancer. Nucl Med Commun. 2019 Mar;40(3):219-27.
22. Onal C, Guler OC, Reyhan M, Yapar AF. Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy. Gynecol Oncol. 2015 Apr;137(1):40-6.
23. Chong GO, Lee WK, Jeong SY, Park SH, Lee YH, Lee SW, et al. Prognostic value of intratumoral metabolic heterogeneity on F-18 fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy. Oncotarget. 2017 Oct 27;8(52):90402-12.
24. Scher N, Castelli J, Depeursinge A, Bourhis J, Prior JO, Herrera FG, et al. ((18)F)-FDG PET/CT parameters to predict survival and recurrence in patients with locally advanced cervical cancer treated with chemoradiotherapy. Cancer Radiother. 2018 May;22(3):229-35.
25. Vercellino L, Groheux D, Thoury A, Delord M, Schlageter MH, Delpech Y, et al. Hypoxia imaging of uterine cervix carcinoma with (18)F-FETNIM PET/CT. Clin Nucl Med. 2012 Nov;37(11):1065-8.
26. Carpenter DJ, Jacobs CD, Wong TZ, Craciunescu O, Chino JP. Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis. Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):356-66.
27. Calles-Sastre L, Mucientes-Rasilla J, San-Frutos Llorente LM, Royuela A, Garcia-Espantaleon Navas M, Herrero Gamiz S, et al. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma. Rev Esp Med Nucl Imagen Mol. 2019 Jan - Feb;38(1):17-21.
28. Liu FY, Lai CH, Yang LY, Wang CC, Lin G, Chang CJ, et al. Utility of (18)F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy: a parallel study of a prospective randomized trial. Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1812-23.
29. Krhili S, Muratet JP, Roche S, Pointreau Y, Yossi S, Septans AL, et al. Use of Metabolic Parameters as Prognostic Factors During Concomitant Chemoradiotherapy for Locally Advanced Cervical Cancer. Am J Clin Oncol. 2017 Jun;40(3):250-5.
30. Park JJ, Kim CK, Park BK. Prognostic value of diffusion-weighted magnetic resonance imaging and (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after concurrent chemoradiotherapy in uterine cervical cancer. Radiother Oncol. 2016 Sep;120(3):507-11.
31. Oh D, Lee JE, Huh SJ, Park W, Nam H, Choi JY, et al. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):549-54.
32. Hong CM, Park SH, Chong GO, Lee YH, Jeong JH, Lee SW, et al. Enhancing prognosis prediction using pre-treatment nodal SUVmax and HPV status in cervical squamous cell carcinoma. Cancer Imaging. 2019 Jun 24;19(1):43.